Thanks to the latest technology — and the data it generates — there’s more promise for pharmaceutical and medical device companies to reduce time to market and improve efficiency.

However, many clinical trial sponsors still have questions about how to effectively gather collective insights and apply them to improve their clinical trials. The result is a call for risk-based quality management (RBQM), which dictates a new way to design, manage and monitor clinical trials. Implementing these guidelines requires a sea of change from companies that have used the same process for decades.

Our new playbook takes a look at how RBQM can yield more efficient, effective results. The playbook highlights:

• Key components of RBQM
• How RBQM helps prove safety and effectiveness
• Why scalability matters
• Steps to effectively implementing RBQM

​